联环药业(600513) - 2019 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 5.28% to CNY 16,675,964.69 year-on-year[5] - Operating revenue grew by 9.30% to CNY 245,916,019.12 compared to the same period last year[5] - Operating profit for Q1 2019 was CNY 20,225,520.76, up from CNY 19,293,647.08 in Q1 2018, reflecting a growth of 4.8%[18] - Net profit for Q1 2019 reached CNY 16,855,374.13, compared to CNY 15,849,877.81 in Q1 2018, representing an increase of 6.3%[18] - The company reported a net profit of CNY 356,712,043.51 in retained earnings, up from CNY 340,036,078.82, reflecting an increase of approximately 4.90%[13] - The company’s total comprehensive income for Q1 2019 was ¥13,701,707.68, reflecting a growth from ¥12,425,911.41 in Q1 2018[20] Assets and Liabilities - Total assets increased by 0.75% to CNY 1,430,709,668.53 compared to the end of the previous year[5] - The company's current assets decreased to CNY 870,248,890.28 from CNY 880,100,607.18, reflecting a decline of approximately 0.97%[11] - Total liabilities decreased to CNY 467,247,586.99 from CNY 473,428,242.42, a decrease of approximately 1.92%[12] - The company's equity attributable to shareholders increased to CNY 946,918,900.20 from CNY 930,242,935.51, an increase of about 1.93%[13] - Total current assets amounted to CNY 880,100,607.18, with cash and cash equivalents at CNY 298,163,174.15[29] - Total non-current assets reached CNY 539,934,342.65, with fixed assets valued at CNY 149,185,579.33 and intangible assets at CNY 38,606,938.87[29] Cash Flow - Net cash flow from operating activities decreased by 312.26% to -CNY 38,824,627.79, primarily due to the endorsement of sales-related invoices[8] - The company experienced a net cash outflow from operating activities of ¥38,824,627.79 in Q1 2019, compared to a net inflow of ¥18,291,342.38 in Q1 2018[23] - The company reported a decrease in cash flow from operating activities due to increased payments for goods and services, totaling ¥176,543,872.66 in Q1 2019, up from ¥92,921,746.91 in Q1 2018[23] - Operating cash inflow for Q1 2019 was ¥362,401,858.84, up 38.2% from ¥262,339,777.18 in Q1 2018[23] Borrowings and Financing - Short-term borrowings increased by 38.58% to CNY 146,900,000.00, indicating a rise in financing activities[8] - The company raised ¥67,900,000.00 through borrowings in Q1 2019, compared to ¥49,500,000.00 in Q1 2018[24] - The net cash flow from financing activities in Q1 2019 was ¥38,880,878.10, a significant improvement from a net outflow of ¥8,196,039.11 in Q1 2018[24] Research and Development - Research and development expenses increased by 39.76% to CNY 2,574,720.32, reflecting higher investment in R&D[8] - Research and development expenses for Q1 2019 were CNY 2,574,720.32, an increase of 40% from CNY 1,842,231.38 in Q1 2018[17] Shareholder Information - The number of shareholders reached 20,823, with the largest shareholder holding 37.09% of the shares[6] - Basic and diluted earnings per share remained stable at CNY 0.06 for both Q1 2019 and Q1 2018[19] Financial Expenses - The company reported a significant increase in financial expenses by 324.76% to CNY 1,701,632.17 due to reduced interest income and increased loans[8] - The company reported a financial expense of CNY 1,701,632.17, significantly higher than CNY 400,607.83 in the same period last year[18]